Medicines Patent Pool

🌟 Exciting News! 🌟 The Medicines Patent Pool (MPP), the Access to Oncology Medicines Coalition (ATOM Coalition), IDA Foundation, and The Max Foundation (Max) are thrilled to announce that MPP sublicensee Hetero has received FDA approval for its generic version of #nilotinib, a treatment for chronic myeloid leukaemia. This marks a significant milestone in increasing access to cancer treatments in low- and middle-income countries. 🎙️ Charles Gore, Executive Director of MPP, highlights this achievement as a landmark in enhancing access to life-saving treatments for non-communicable diseases. 🎙️ Dan Milner, Executive Director of the Union for International Cancer Control (UICC)-led ATOM Coalition, emphasises the critical advancement in broadening access to #oncology drugs in underserved regions. 🎙️ Harm Veerkamp, NCDconnect Director, expresses excitement over this milestone, bringing hope to those affected by CML. 🎙️ Pat Garcia-Gonzalez, CEO of The Max Foundation, underscores the commitment to expanding access to quality drugs in LMICs. 🎙️ Dr. Vamsi Krishna Bandi, MD & CEO of Hetero, proudly states their dedication to expanding access to vital cancer treatments with their advanced manufacturing facilities. This development is crucial, considering the increasing #cancer cases and mortality in LMICs. Nilotinib, part of the World Health Organization Model List of Essential Medicines, offers an affordable treatment option for CML patients. Together, we are making a tangible difference for #cancer patients worldwide! 🌍💊 📃 Access the joint statement: https://bit.ly/3ZA1pBj #CancerTreatment #GlobalHealth #FDAApproval #MPP #ATOMCoalition #CML #ChronicMyeloidLeukaemia Unitaid, Swiss Agency for Development and Cooperation, Ministère des Affaires étrangères français, Ministry of Foreign Affairs of Japan, World Intellectual Property Organization – WIPO, Government of Canada

Check out the latest #MedsPaL newsletter! You will find: ✅ a one-hour webinar recording where we explore the enhanced MedsPaL interface and its new features. 📽️ Watch the full video to gain valuable insights! ✅ the latest additions and updates, including new medicines, vaccines, and ✅ the latest news about MPP. Stay informed and engaged with the progress we are making towards improving #GlobalHealth. 🌍 🔗 Access the newsletter here: https://bit.ly/4fw43xE #PublicHealth #Access2Meds #EssentialMedicines #Patents #VoluntaryLicensing #Database #OpenAccess

📢 Request for Proposal: Visual Identity & Branding MPP is looking for partner(s) to create a graphic charter and branding assets for our internal and external #communication. Help us strengthen our impact in #globalhealth. 🗓️ Deadline for applying: 31 January 2025 🔗 Learn more: https://bit.ly/403nLg1 #RFP #Design #branding #PublicHealth #RequestForProposal

💡 Did you know? The new version of #MedsPaL introduces advanced reporting and licensing tools to make #GlobalHealth intellectual property data more accessible than ever!  Key features include:  ✅The Reports view now includes interactives maps, donut charts, and timelines, giving you a dynamic perspective on patent statuses and geographic distribution.  ✅A dedicated licence tab in both the Table and Reports views, providing in-depth insights into licensing agreements.  ✅These updates are designed to help stakeholders in global health better navigate and utilise crucial data for decision-making.  Explore MedsPaL’s new features here: medspal.org Unitaid, Swiss Agency for Development and Cooperation, Ministry of Foreign Affairs of Japan, Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH #GlobalHealth #PublicHealth #Access2Meds #HealthForAll #IntellectualProperty #PatentLaw#Innovation#MedsPaL

🌍 Applauding Spain’s New Pharmaceutical Strategy (2024-2028) 🇪🇸 We’re excited to see Spain lead the way with a strategy that prioritizes innovation, access, and social impact in healthcare. 📌 Key Highlights: • Access Guidelines: Developers receiving public funding will follow models ensuring a social return on public investment. • Support for MPP & DNDi: Honoured to see our models promoted in areas of strategic importance like national security and global health. This visionary approach aligns with our work in access and pandemic preparedness, including integrating ‘affordable access plan provisions’ into licensing and funding agreements. We hope to see similar approaches considered by other Member States! 👏 A big step forward—congratulations to all involved! 🔗 Read more: Spanish Pharmaceutical Strategy 2024-2028 https://ow.ly/Qcgv50UtawZ 👉See what MPP is doing in Upstream Access https://ow.ly/Wi6y50Utax0 #PharmaceuticalStrategy #GlobalHealth #AccessToMedicines #Innovation #HealthEquity Drugs for Neglected Diseases initiative - DNDi Javier Padilla

💊 Breaking Barriers to Access: Nilotinib Now Available on NCDconnect! 🌍 Patients with Chronic Myeloid Leukaemia (CML) in low- and middle-income countries (LMICs) now have new hope! Following yesterday’s exciting news of Hetero’s FDA approval for their generic nilotinib, this access programme—built through a collaborative effort led by Medicines Patent Pool, IDA Foundation, The Max Foundation, and the ATOM Coalition—has made this life-saving treatment accessible via the NCDconnect Digital Procurement Platform. Discover in our latest blog how this initiative is reducing costs, expanding access, and ultimately saving lives. ➡ https://lnkd.in/e9SEQUgM #GlobalHealth #CML #AccessToMedicines #NCDconnect #ATOMCoalition Union for International Cancer Control (UICC)

📢 Exciting update from the 1st Trilateral Technical Symposium on “Strengthening Manufacturing Capacities to Respond to the Non-Communicable Diseases (#NCDs) Burden” held earlier today at the World Trade Organization in #Geneva 🇨🇭! 🎙️ MPP's Esteban Burrone delivered an insightful presentation titled "The Way Forward - Promoting innovation and access to health technologies for NCDs." He highlighted the rapid development of new medicines for NCDs, with an average of 48 new drug approvals per year by the USFDA this decade, a significant increase from previous decades. The presentation also addressed the challenges in disseminating these innovations in low- and middle-income countries. 🤝🏽 Esteban emphasised the importance of licensing and technology transfer in accelerating access to essential medicines, showcasing how partnerships have enabled the supply of 44 billion doses of treatments in over 140 countries🌍💊 . 🔗 Read our latest report on how voluntary licensing can be good for #health and smart for #business: https://bit.ly/3Xvjm2Z 💻Watch the recording of the session: https://lnkd.in/dcd2eugd World Health Organization, World Intellectual Property Organization – WIPO

🔬💡 Great news with the publication of the preclinical evaluation of the mRNA COVID-19 vaccine candidate AfriVac 2121 produced under the mRNA Technology Transfer Programme in the Vaccine journal: 📘 🇿🇦 “...To address these disparities, the mRNA Technology Transfer Programme, coordinated and led by the World Health Organization and the Medicines Patent Pool, was launched. A consortium has been set up in South Africa to develop a platform for manufacturing mRNA vaccines. In this study, the preclinical evaluation of the mRNA COVID-19 vaccine candidate, AfriVac 2121 (Wuhan) manufactured in December 2022 was conducted...” 📄 Access to the full study here: https://lnkd.in/eMVTYK5G #mRNAprogramme #AccessToMedicines #Afrigen #TechnologyTransfer #AfriVac2121

🎙️ Today, Rhoda Igweta of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) delivered a statement on behalf of the Global Accelerator for Paediatric Formulations Network (GAP-f) partners at the 55th UNAIDS Programme Coordinating Board (PCB). The statement highlighted the ongoing challenges in providing HIV treatment for children and the critical need to address these gaps. 👶🏽 🧒🏽 Despite significant progress, children living with #HIV still face lower rates of viral suppression compared to adults, leading to higher mortality and morbidity. 🫗 💊 The statement emphasised the importance of developing and introducing optimal formulations for children to improve their treatment outcomes. 💪🏽 GAP-f partners, including EGPAF, USAID, and the Medicines Patent Pool, are committed to closing this treatment gap by collaborating with various stakeholders across the drug life cycle. This includes the timely transition to child-friendly regimens like paediatric ALD and darunavir/ritonavir oral tablets. 🔗 Read more: https://bit.ly/4gaIXpY #BetterMeds4Kids #GlobalHealth #HIV #GAPf #HealthEquity #EndAIDS2030

📢 End-of-Year Message from MPP Executive Director Charles Gore 📢 ✨ As 2️⃣ 0️⃣ 2️⃣ 4️⃣ comes to a close, we reflect on a year of significant achievements and ongoing challenges in global health. From our transformative partnerships to advancements in pandemic preparedness and research, we remain committed to ensuring equitable access to life-saving medicines and health technologies. 🤝🏽 Join us in celebrating our progress and renewing our resolve to address the needs of people in low- and middle-income countries. Together, we can deliver transformative change and build a healthier future for all. 📃 Read the full message here: https://bit.ly/4feITnP #GlobalHealth #HealthEquity #PublicHealth #MPP #EndOfYearMessage #CharlesGore #TransformativeChange #UHCDay2024 #HealthForAll #UniversalHealthCoverage #UHC2030 Unitaid, Swiss Agency for Development and Cooperation, Ministry of Foreign Affairs of Japan, Ministère des Affaires étrangères français, Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, World Intellectual Property Organization – WIPO, Public Health Agency of Canada | Agence de la santé publique du Canada